Key statistics
On Thursday, Innate Pharma SA (IPHA:NSQ) closed at 1.70, 31.78% above the 52 week low of 1.29 set on Nov 18, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.65 |
---|---|
High | 1.70 |
Low | 1.56 |
Bid | 1.30 |
Offer | 2.00 |
Previous close | 1.69 |
Average volume | 11.57k |
---|---|
Shares outstanding | 80.97m |
Free float | 62.13m |
P/E (TTM) | -- |
Market cap | 130.44m USD |
EPS (TTM) | -0.4414 USD |
Data delayed at least 15 minutes, as of Nov 21 2024 20:58 GMT.
More ▼
- Innate Pharma Releases Its 2025 Financial Calendar
- Innate Pharma Announces Publication in Science Immunology Highlighting Innovative Next-generation ANKET® IPH6501
- Innate Pharma Reports Third Quarter 2024 Business Update and Financial Results
- Innate Pharma Highlights Data From Its Innovative Oncology Portfolio Selected for the SITC Annual Meeting 2024
- Innate Pharma Announces Conference Call and Webcast for Third Quarter 2024 Results and Business Updates
- Innate Pharma Announces Its Participation in Upcoming Investor Conferences
- Innate Pharma Appoints Jonathan Dickinson as New Chief Executive Officer and Chairman of the Executive Board
- Innate Pharma to Host KOL Scientific Symposium on Immunotherapy in New York on October 3, 2024
- Innate Pharma Announces FDA Clearance of the IND for IPH4502, a Nectin-4 ADC to Be Developed in Solid Tumors
- Innate Pharma Reports First Half 2024 Business Update and Financial Results
More ▼